Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 12, 2010

miRagen to Assess RXi’s Technology Against miRNA Targets of Interest

  • RXi Pharmaceuticals and miRagen Therapeutics entered into a collaboration to evaluate RXi’s rxRNA™ technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas. Each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds.

    RXi says that its version of RNAi compounds, developed on the rxRNA platform, provide an alternative to siRNAs. These include rxRNAori™, rxRNAsolo™, and sd-rxRNA™ (self-delivering RNA), which are distinct from classic siRNAs.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »